Inhibitory effects of resveratrol on human mast cell degranulation, cytokine, chemokine and leukotriene release

Adriana Catalli, Clayton MacDonald, Priyanka Pundir, Marianna Kulka

Department of Biomedical Sciences, Atlantic Veterinary College, Charlottetown, Canada.
National Research Council, Charlottetown, Canada.
National Research Council, Edmonton, Canada.

DOI: 10.4236/oji.2012.24022                

Abstract

Resveratrol, a polyphenol abundant in peanuts, red wine and the skin of grapes, has been shown to have anti-cancer, anti-oxidant and anti-inflammatory activities, and may also have beneficial effects on allergic inflammation. We investigated the effects of resveratrol on human mast cell activation in comparison to the anti-allergy drug tranilast. In LAD2 mast cells, both resveratrol and tranilast inhibited degranulation induced by the mast cell activators substance P, IgE/anti-IgE, and compound 48/80. Resveratrol inhibition was immediate, preventing degranulation when added simultaneously to physiological stimuli, and the effect was sustained for up to 24 hrs. The inhibitory effect was not cAMP dependent, but may be attributable to calcium modulation, as resveratrol, and to a lesser extent tranilast, prevented substance P-induced increases in intracellular calcium. Resveratrol attenuated substance P-induced TNF and MCP-1 production and inhibited IgE-mediated release of cysteinyl leukotrienes, whereas tranilast was ineffective. Furthermore, both resveratrol and tranilast reduced expression of the high affinity IgE receptor, FcεRI, on LAD2 cells. The effects of resveratrol on mast cell activation were more marked in human primary CD34+-derived mast cells (HuMC), and the polyphenol was significantly more efficacious than tranilast in these cells. In conclusion, resveratrol inhibited key aspects of human mast cell activation to physiological stimuli, and was comparable, if not more efficacious than the anti-allergy drug tranilast. Thus, resveratrol may be an effective therapeutic agent for the treatment of allergic disease.

Keywords

Mast Cells; Resveratrol; Tranilast; IgE; Substance P; Leukotrienes

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Schroder, G., Brown, J.W. and Schroder, J. (1988) Molecular analysis of resveratrol synthase. cDNA, genomic clones and relationship with chalcone synthase. European Journal of biochemistry/FEBS, 172, 161-169.
[2]	Fremont, L. (2000) Biological effects of resveratrol. Life Sciences, 66, 663-673. doi:10.1016/S0024-3205(99)00410-5
[3]	Baur, J.A. and Sinclair, D.A. (2006) Therapeutic potential of resveratrol: The in vivo evidence. Nature Reviews, Drug Discovery, 5, 493-506. doi:10.1038/nrd2060
[4]	Ragazzi, E., Froldi, G. and Fassina, G. (1988) Resveratrol activity on guinea pig isolated trachea from normal and albumin-sensitized animals. Pharmacological Research Communications, 20, 79-82. doi:10.1016/S0031-6989(88)80846-4
[5]	Kimura, Y., Okuda H. and Arichi, S. (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochimica et Biophysica Acta, 834, 275-278. doi:10.1016/0005-2760(85)90167-5
[6]	Kimura, Y., Okuda, H. and Kubo, M. (1995) Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes. Journal of Ethnopharmacology, 45, 131-139. doi:10.1016/0378-8741(94)01206-F
[7]	Martinez, J. and Moreno, J.J. (2000) Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochemical Pharmacology, 59, 865-870. doi:10.1016/S0006-2952(99)00380-9
[8]	Metz, M., et al. (2007) Mast cells in the promotion and limitation of chronic inflammation. Immunological Reviews, 217, 304-328. doi:10.1111/j.1600-065X.2007.00520.x
[9]	Stone, K.D., Prussin, C. and Metcalfe, D.D. (2010) IgE, mast cells, basophils, and eosinophils. The Journal of Allergy and Clinical Immunology, 125, S73-S80. doi:10.1016/j.jaci.2009.11.017
[10]	Lee, M., et al. (2009) Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. International Immunopharmacology, 9, 418-424. doi:10.1016/j.intimp.2009.01.005
[11]	Baolin, L., et al. (2004) Resveratrol inhibits the release of mediators from bone marrow-derived mouse mast cells in vitro. Planta Medica, 70, 305-309. doi:10.1055/s-2004-818940
[12]	Koo, N., Cho, D., Kim, Y., Choie, H.J. and Kim, K.M. (2006) Effects of resveratrol on mast cell degranulation and tyrosine phosphorylation of the signaling components of the IgE receptor. Planta Medica, 72, 659-661. doi:10.1055/s-2006-931568
[13]	Cheong, H., Ryu, S.Y. and Kim, K.M. (1999) Anti-allergic action of resveratrol and related hydroxystilbenes. Planta Medica, 65, 266-268. doi:10.1055/s-2006-960773
[14]	Quilez, A.M., Saenz, M.T., Garcia, M.D. and de la Puerta, R. (2004) Phytochemical analysis and anti-allergic study of Agave intermixta Trel and Cissus sicyoides L. The Journal of pharmacy and pharmacology, 56, 1185-1189. doi:10.1211/0022357044102
[15]	Kang, O.H., et al. (2009) Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: Pivotal roles of NF-kappaB and MAPK. Pharmacological research: The Official Journal of the Italian Pharmacological Society, 59, 330-337.
[16]	Walle, T., Hsieh, F., DeLegge, M.H., Oatis Jr., J.E. and Walle, U.K. (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 32, 1377-1382. doi:10.1124/dmd.104.000885
[17]	Goldberg, D.M., Yan, J. and Soleas, G.J. (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clinical biochemistry, 36, 79-87. doi:10.1016/S0009-9120(02)00397-1
[18]	Metcalfe, D.D., Kaliner, M. and Donlon, M.A. (1981) The mast cell. Critical Reviews in Immunology, 3, 23-74.
[19]	Pearce, F.L. (1985) Calcium and mast cell activation. British Journal of Clinical Pharmacology, 20, 267S-274S. doi:10.1111/j.1365-2125.1985.tb02812.x
[20]	Weston, M.C., Anderson, N. and Peachell, P.T. (1997) Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. British Journal of Pharmacology, 121, 287-295. doi:10.1038/sj.bjp.0701115
[21]	Weston, M.C. and Peachell, P.T. (1998) Regulation of human mast cell and basophil function by cAMP. General pharmacology, 31(5): p. 715-9. doi:10.1016/S0306-3623(98)00080-9
[22]	Small-Howard, A.L., Shimoda, L.M., Adra, C.N. and Turner, H. (2005) Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. The Biochemical Journal, 388, 465-473.
[23]	Tsuji, T., et al. (2004) Differential effects of beta2-adrenoceptor desensitization on the IgE-dependent release of chemical mediators from cultured human mast cells. Biological & Pharmaceutical Bulletin, 27, 1549-1554. doi:10.1248/bpb.27.1549
[24]	Serra-Pages, M., et al. (2012) E-prostanoid 2 receptors dampen mast cell degranulation via cAMP/PKA-mediated suppression of IgE-dependent signaling. Journal of Leukocyte Biology, 92, 1155-1165. doi:10.1189/jlb.0212109
[25]	Manna, S.K., Mukhopadhyay, A. and Aggarwal, B.B. (2000) Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. Journal of Immunology, 164, 6509-6519.
[26]	Holmes-McNary, M. and Baldwin Jr., A.S. (2000) Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Research, 60, 3477-3483.